<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260920</url>
  </required_header>
  <id_info>
    <org_study_id>FTDOXY17EF</org_study_id>
    <nct_id>NCT03260920</nct_id>
  </id_info>
  <brief_title>Intranasal Oxytocin for Frontotemporal Dementia</brief_title>
  <acronym>FOXY</acronym>
  <official_title>A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berry Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and effects on behaviour of&#xD;
      Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive&#xD;
      saline substance that contains no medication) in participants with frontotemporal&#xD;
      dementia/Pick's disease. This study will take place in approximately 15 centres across Canada&#xD;
      and the United States. Approximately 112 patients in total will be enrolled in this study. In&#xD;
      the first phase we will examine which of three different dosing schedules of oxytocin may be&#xD;
      more effective. In the second phase of the study, patients entering the study will be&#xD;
      randomized to the oxytocin dosing schedule that appeared most effective in the first phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>A Proof-of-Concept Double Blind Randomized Controlled, Cross-Over Adaptive Design Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Pilot data from our two prior studies of oxytocin in FTD have driven the selection of the NPI as the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in emotional facial expression recognition performance</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Revised Self-Monitoring Scale score</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified Clinicians Global Impression of Change (apathy) scores</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon</intervention_name>
    <description>Intranasal Oxytocin</description>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_label>Medium Dose</arm_group_label>
    <other_name>Intranasal Oxytocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable FTD (behavioural variant FTD, FTD-semantic subtype or&#xD;
             FTD-Progressive Nonfluent Aphasia) with supportive brain imaging (centrally rated&#xD;
             frontotemporal atrophy score of 2 or greater on brain MRI or CT) or known FTD causing&#xD;
             genetic mutation.68&#xD;
&#xD;
          -  Current symptoms of social apathy/indifference as measured by NPI apathy/indifference&#xD;
             severity subscale score &gt;= 2 indicating the presence of moderate to marked levels of&#xD;
             apathy/indifference.&#xD;
&#xD;
          -  Study partner who consents to study participation and who cares for/visits the patient&#xD;
             daily for at least 3 hours/day and who can administer all trial medications.&#xD;
&#xD;
          -  FTLD-CDR score 0-2.&#xD;
&#xD;
          -  MMSE &gt;10.&#xD;
&#xD;
          -  Stable baseline medications related to cognition or behaviour for &gt;=30 days such as&#xD;
             acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents,&#xD;
             other mood stabilizers, benzodiazepines.&#xD;
&#xD;
          -  Written informed consent must be obtained and documented (from the patient or, where&#xD;
             jurisdictions allow it, from their substitute decision maker).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of stroke, other neurologic or psychiatric disorder other than FTD that is&#xD;
             considered to better account for behavioural symptoms.&#xD;
&#xD;
          -  History of a myocardial infarction within the last two years or congestive heart&#xD;
             failure.&#xD;
&#xD;
          -  Current uncontrolled hypertension&#xD;
&#xD;
          -  Current bradycardia (rate &lt; 50 beats per minute/bpm) or tachycardia (rate &gt; 100 bpm)&#xD;
&#xD;
          -  Current hyponatremia (Na &lt;135 mEq/L)&#xD;
&#xD;
          -  Current use of topical prostaglandin medications applied to the cervix.&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding, or planning to conceive within the study&#xD;
             period.&#xD;
&#xD;
          -  Use of any investigational or experimental drug or device within the last 60 days&#xD;
             prior to screening or within 5 half-lives of the experimental drug, whichever is&#xD;
             longer.&#xD;
&#xD;
          -  Participant has speech difficulties that in the opinion of the investigator would be&#xD;
             incompatible with neuropsychology and safety assessments&#xD;
&#xD;
          -  History of cancer except:&#xD;
&#xD;
               -  If considered to be cured&#xD;
&#xD;
               -  If not being actively treated with anti-cancer therapy or radiotherapy and, in&#xD;
                  the opinion of the investigator, not likely to require treatment in the ensuing 5&#xD;
                  years&#xD;
&#xD;
               -  For prostate cancer or basal cell carcinoma, no significant progression over the&#xD;
                  previous 2 years&#xD;
&#xD;
          -  Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic,&#xD;
             gastrointestinal or neurological disease. If the condition has been stable for at&#xD;
             least the past year and is judged by the investigator not to interfere with the&#xD;
             patient's participation in the study, the patient may be included.&#xD;
&#xD;
          -  For the CSF sub-study, current use of anticoagulant medications (warfarin,&#xD;
             rivaroxaban, etc.).&#xD;
&#xD;
          -  Plan for FTD patient to be placed into long-term care or plan for hospital admission&#xD;
             for any kind of treatment within study period or if caregiver plans for&#xD;
             holidays/respite care &gt; 3 days during study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Chavez</last_name>
      <phone>310-478-3711</phone>
      <phone_ext>48176</phone_ext>
      <email>dianachavez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Mario Mendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Koestler</last_name>
      <phone>415-476-0661</phone>
      <email>mary.koestler@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Boxer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni White, MS</last_name>
      <phone>410-550-6486</phone>
      <email>twhite46@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Chiadi U Onyike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Stein</last_name>
      <phone>212-305-6284</phone>
      <email>cs4125@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Huey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Adams</last_name>
      <phone>206-221-9038</phone>
      <email>adamsali@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kimiko Domoto-Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahlee Marian</last_name>
      <phone>(604) 822-0324</phone>
      <email>tahlee.marian@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Robin Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Jesso, BA</last_name>
      <phone>519-646-6000</phone>
      <email>cognitiveneurology@sjhc.london.on.ca</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Finger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Saad</last_name>
      <phone>(416) 480-6100</phone>
      <phone_ext>1620</phone_ext>
      <email>flavia.saad@sri.utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Mario Masellis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Mora-Fisher</last_name>
      <phone>(416) 603-5800</phone>
      <email>daniela.mora-fisher@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Carmela Tartaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Friedman</last_name>
      <phone>(514) 398-5750</phone>
      <email>michal.friedman@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Simon Ducharme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1J1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megane Lacombe-Thibault</last_name>
      <phone>418-649-0252</phone>
      <email>megane.lacombe-thibault@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Robert LaForce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>frontotemporal dementia</keyword>
  <keyword>apathy</keyword>
  <keyword>empathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

